An in-depth look to MEDIGEN BIOTECHNOLOGY CORPORATION operating, investing, and financing activities

3176 free cash flow for Q3 24 is -51.52 M TWD. For 2023, 3176 free cash flow was -607.81 M TWD and operating cash flow was -569.4 M TWD.